Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
PHASE3
The primary objective of this study is to evaluate the efficacy of switchin...
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
PHASE3
This study will evaluate the non-inferiority of Stribild® (elvitegravir/cob...
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
PHASE3
The purpose of this randomized, open-label, multicenter, active-controlled ...
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study
PHASE2
The purpose of this study is to evaluate the long-term safety and tolerabil...
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
N/A
The purpose of this study is to describe the effectiveness of darunavir/cob...
Status
Completed
Location
Multiple Locations
Start Date
2016-07-22
Trial ID
NCT02926456
Kuwa Free! - Live Free!
NA
The study investigators are conducting foundational pharmacokinetic (PK) an...
Status
Recruiting
Location
Academic Model Providing Access to Healthcare (AMPATH) Moi Teaching And Referral Hospital (MTRH)